KRAS and colorectal carcinoma: Only recently has the KRAS G12C mutation been successfully targeted [20], and treatment with an inhibitor of KRAS G12C both alone and in combination with cetuximab produced early encouraging responses in patients with KRAS G12C-mutated CRC [21–23].